UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

British journal of haematology, 2014-09, Vol.166 (6), p.891-901

2014

Volltextzugriff (PDF)

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1582-1589

2006

Volltextzugriff (PDF)

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

American journal of hematology, 2007-08, Vol.82 (8), p.725-728

2007

Volltextzugriff (PDF)

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

British journal of haematology, 2010-07, Vol.150 (2), p.200-208

2010

Volltextzugriff (PDF)

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4095-4102

2004

Volltextzugriff (PDF)

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

British journal of haematology, 2007-02, Vol.136 (3), p.439-447

2007

Volltextzugriff (PDF)

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Cancer, 2006-09, Vol.107 (6), p.1294-1302

2006

Volltextzugriff (PDF)

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

British journal of haematology, 2013-12, Vol.163 (5), p.611-620

2013

Volltextzugriff (PDF)

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

British journal of haematology, 2014-10, Vol.167 (2), p.177-184

2014

Volltextzugriff (PDF)

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Blood, 2005-06, Vol.105 (12), p.4573-4575

2005

Volltextzugriff (PDF)

Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma

Cancer, 2005-08, Vol.104 (4), p.781-787

2005

Volltextzugriff (PDF)

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

Blood, 2002-12, Vol.100 (13), p.4351-4357

2002

Volltextzugriff (PDF)

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

Cancer, 2002-03, Vol.94 (6), p.1731-1738

2002

Volltextzugriff (PDF)

Thalidomide for patients with recurrent lymphoma

Cancer, 2004-03, Vol.100 (6), p.1186-1189

2004

Volltextzugriff (PDF)

Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma

The American journal of surgical pathology, 2004-04, Vol.28 (4), p.489-495

2004

Volltextzugriff (PDF)

Subdiaphragmatic stage I & II Hodgkin’s disease: long-term follow-up and prognostic factors

International journal of radiation oncology, biology, physics, 1998-07, Vol.41 (5), p.1047-1056

1998

Volltextzugriff (PDF)

Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma

Cancer research (Chicago, Ill.), 1988-10, Vol.48 (19), p.5557-5564

1988

Volltextzugriff (PDF)

Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model

Journal of clinical oncology, 1991-05, Vol.9 (5), p.762-769

1991

Volltextzugriff (PDF)

Prognostic value of serum beta-2 microglobulin in low-grade lymphoma

Annals of internal medicine, 1991-05, Vol.114 (10), p.855

1991

Volltextzugriff (PDF)

Significance of tumor size and radiation dose to local control in Stage I–III diffuse large cell lymphoma treated with CHOP-Bleo and radiation

International journal of radiation oncology, biology, physics, 1995, Vol.31 (1), p.3-11

1995

Volltextzugriff (PDF)

Role of the gallium scan in Hodgkin's disease

Cancer, 1990-03, Vol.65 (5), p.1090-1096

1990

Volltextzugriff (PDF)

Risk Classification as the Basis for Clinical Staging of Diffuse Large-Cell Lymphoma Derived From 10-Year Survival Data

Blood, 1989-08, Vol.74 (2), p.551-557

1989

Volltextzugriff (PDF)

Prognostic role of serum β2-microglobulin in Hodgkin's disease

Journal of clinical oncology, 1993, Vol.11 (6), p.1108-1111

1993

Volltextzugriff (PDF)

Aggressive Non-Hodgkin's Lymphomas in Immunocompromised Homosexual Males

Blood, 1985-09, Vol.66 (3), p.655-659

1985

Volltextzugriff (PDF)

Low-grade lymphomas : new entities and treatment concepts

Medical oncology (Northwood, London, England), 1995-09, Vol.12 (3), p.131-142

HAGEMEISTER, F. B

1995

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaHematologic And Hematopoietic Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(32)
Medical Sciences
(32)
Humans
(31)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(30)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Middle Aged
(23)
Adult
(22)
Male
(22)
Female
(20)
Aged
(17)
Oncology
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Hematology
(12)
Neoplasm Staging
(12)
Treatment Outcome
(12)
Tumors
(9)
Disease-Free Survival
(8)
Follow-Up Studies
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

Thalidomide for patients with recurrent lymphoma

Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma

Subdiaphragmatic stage I & II Hodgkin’s disease: long-term follow-up and prognostic factors

Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma

Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model

Prognostic value of serum beta-2 microglobulin in low-grade lymphoma

Significance of tumor size and radiation dose to local control in Stage I–III diffuse large cell lymphoma treated with CHOP-Bleo and radiation

Role of the gallium scan in Hodgkin's disease

Risk Classification as the Basis for Clinical Staging of Diffuse Large-Cell Lymphoma Derived From 10-Year Survival Data

Prognostic role of serum β2-microglobulin in Hodgkin's disease

Aggressive Non-Hodgkin's Lymphomas in Immunocompromised Homosexual Males

Low-grade lymphomas : new entities and treatment concepts

Aktive Filter

Suchergebnisse filtern